***ADCK3* mutations with epilepsy, stroke-like episodes and ataxia: a POLG mimic?**

Omar Hikmat1,3, Charalampos Tzoulis2,3, Per M. Knappskog3,4, Stefan Johansson4,5,6, Helge Boman3,4 , Paweł Sztromwasser4, Espen Lien⁷, Eylert Brodtkorb⁸’⁹, Daniele Ghezziˡ⁰, Laurence A. Bindoff2,3

1. Department of Pediatrics, Haukeland University Hospital, 5021 Bergen, Norway

2. Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway

3. Department of Clinical Medicine (K1), University of Bergen, Norway

4. Center for Medical Genetics and Molecular Medicine, Haukeland University

Hospital, Bergen, Norway

5. Department of Biomedicine, University of Bergen, Bergen, Norway

6. K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen, Bergen, Norway

7. Department of Pediatrics, St. Olav's University Hospital Trondheim, Trondheim, Norway.

8. Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway.

9. Department of Neurology and Clinical Neurophysiology, St. Olav's University Hospital, Trondheim, Norway.

10. Foundation IRCCS Neurological Institute “Carlo Besta”, Unit of Molecular Neurogenetics, Milan, Italy

**Correspondence to:**

Professor Laurence Bindoff

Department of Neurology

University of Bergen

Haukeland University Hospital

5021 Bergen, Norway

Tel: +47 55975096

Fax: +47 55975164

e-mail:laurence.bindoff@nevro.uib.no

**Keywords:** *ADCK3, CABC1,*Coenzyme Q10,mitochondria,*POLG,*ataxia,epilepsia partialis continua**,** stroke like episodes.

**Total number of words:** 3481

**Disclosure of conflicts of interest:**

The authors declare no financial or other conflicts of interest.

**ABSTRACT**:

**Background**

Defects of CoQ10 metabolism cause a variety of disorders ranging from isolated myopathy to multisystem involvement. *ADCK3* is one of several genes associated with CoQ10 deficiency presenting with progressive cerebellar ataxia, epilepsy, migraine and psychiatric disorders. Diagnosis is challenging due to the wide clinical spectrum and overlap with other mitochondrial disorders.

**Methods**

We provide a detailed description of 3 new and one previously reported patients from three families with novel and known mutations in the *ADCK3* gene focussing on the epileptic semiology and response to treatment. In 3 patients, we used exome sequencing to identify the *ADCK3* mutation and in 2 measurement of skeletal muscle CoQ10 was performed.

**Results**

All four patients presented with childhood onset epilepsy and progressive cerebellar ataxia. Three patients had epilepsia partialis continua and stroke-like episodes affecting the posterior brain. EEG showed focal epileptic activity in the occipital and temporal lobes. Genetic investigation revealed *ADCK3* mutations in all patients including a novel change in exon 15: c.T1732G, p.F578V. There was no apparent genotype-phenotype correlation.

**Conclusion**

*ADCK3* mutations cause a combination of progressive ataxia and acute epileptic encephalopathy with stroke-like episodes. The clinical, radiological and electrophysiological features of this disorder mimic the phenotype of polymerase gamma (POLG) related encephalopathy. We suggest that *ADCK3* mutations should be considered in the differential diagnosis of mitochondrial encephalopathy with POLG-like features.

**INTRODUCTION**:

Coenzyme Q10 (CoQ10), the major form of endogenous ubiquinone in humans, is a fat-soluble substance present in most eukaryotic cells. It is synthesized in the mitochondrial inner membrane and comprises a benzoquinone ring, derived from tyrosine or phenylalanine and decaprenyl tail, which is synthesized in the cytosol via the mevalonate pathway. The process of CoQ10 synthesis is complex and involves several enzymatic steps (1). The major function of CoQ10 is to transport electrons from complexes I and II to complex III in the respiratory chain, but it is also required for pyrimidine nucleoside biosynthesis and is involved in modulating apoptosis (2). It is still not clear whether the pathophysiological mechanism of CoQ10 deficiency reflects the bioenergetic defect or to impairment of its other functions (3).

Thirteen genes are known to be involved in the biosynthesis of human CoQ10 (*PDSS, PDSS2, COQ2, COQ3, COQ4, COQ5, COQ6, COQ7, ADCK3, ADCK4, COQ9, COQ10a, COQ10B*). Mutations in eight of them (*PDSS1, PDSS2, COQ2, COQ4, COQ6, ADCK3, ADCK4, COQ9*) are associated with human diseases (4). CoQ10 deficiency comprises a continuum of overlapping phenotypes classified either as primary, i.e. caused by mutations in genes involved in CoQ10 synthesis, or secondary, those caused by defects in genes unrelated to CoQ10 biosynthesis, but which result in CoQ10 deficiency.

Five major phenotypes have been described (3) with primary CoQ10 deficiency including myopathic and encephalopathic forms, but overlap is common. Diagnosis of CoQ10 deficiency disorders is challenging especially in the paediatric population where patients often present with non-specific phenotypes such as neonatal seizures or encephalopathy.

We report a series of 4 patients with *ADCK3* mutations (MIM606980) and CoQ10 deficiency presenting with a phenotype resembling that seen in polymerase gamma (POLG) related disease (5). The clinical features of these cases are compared with previously reported cases with particular focus in the seizures frequency, semiology and response to treatment.

**PATIENTS AND METHODS**:

Our study was approved by the Regional Committee for Medical and Health Research Ethics, Western Norway (IRB00001872). All study participants provided written informed consent. The clinical and genetic features of the patients are summarized in table 1.

**Case reports**

Patient 1 is a 35 year old woman, the second child of non-consanguineous parents. After a normal birth and early psychomotor development, she developed focal and secondarily generalized seizures aged 7 years. From her early teens, she became increasingly ataxic and developed a fine tremor involving the head and upper extremities. Examination at the age of 34 years showed cerebellar dysarthria and mild gait and appendicular ataxia. Muscle tone and power, deep tendon reflexes and Romberg test were all normal. At 34 she remains ambulatory and works full-time. Her inter-ictal EEG shows bilateral occipital and right temporal epileptic activity. MRI at the age 31 years showed mild cerebellar atrophy affecting mainly the superior vermis and high T2-signal symmetrically in the nuclei dentatii (“white teeth” sign). Treatment with Ubiquinone 300 mg 3 times daily for 6 months has not yet given any apparent improvement.

Patient 2 is a 34 year old man, the third child of healthy parents. His similarly affected older sister died aged 22 years (Patient 3). He was born at term after a normal pregnancy and delivery and walked aged 12 months, with an unsteady gait. He developed focal and generalized seizures aged 7 years. At age 8 had one episode of epilepsia partialis continua affecting the right arm and leg and a stroke-like episode with vomiting, headache and right hemiparesis. He also had migraine-like episodes at age of 18 with two episodes of severe headache with nausea leaving him bedridden for one day. He has been seizure free from the age of 29 years on lamotrigine and sodium valproate. He developed progressive ataxia from late teenage and examination aged 33 years showed marked scanning dysarthria, gait ataxia, dysmetria, intension tremor and dysdiadochokinesia. He scored 11 points on the SARA scale (scale for assessment and rating of ataxia). Inter-ictal EEG shows focal, bilateral occipito-temporal epileptic spikes. MRI of the brain showed cerebellar atrophy with “white teeth” sign and a focal, cortical stroke-like lesion in the right occipital lobe (figure 1A-C). Cerebral FDG-PET showed cerebellar hypometabolism and focal, asymmetrical hypometabolism in the right occipital lesion (Figure 1D-E). Treatment with Ubiquinone 300 mg 3 times daily was started aged 33 years and at six month follow-his score had fallen to 6 points on the SARA scale. Both patient and family reported improved balance, coordination and daily function. MRI of the brain remained unchanged.

Patient 3, the older sister of patient 2, was born at term after normal pregnancy and delivery. She developed normally until age 3 years when she developed motor difficulties, dysarthria, and progressive ataxia. She developed epilepsy aged 7 years, which was classified as focal with secondary generalization. EEG showed bilateral multifocal temporo-occipital epileptic spikes. Her ataxia worsened in her late teens and she developed tremor and cognitive impairment and was admitted repeatedly with status epilepticus and epilepsia partialis continua. MRI showed cerebellar atrophy with dentate hyperintensity and multiple bilateral cortical stroke-like lesions throughout the cortex. She died at the age of 22 years in intractable status epilepticus.

Patient 4, a 22 years old women, has been published previously (6), but is included here with a more detailed clinical description. She is the first child of healthy non consanguineous parents. She developed motor difficulties and ataxia at 2 years and epilepsy at 3 that was classified as focal with secondary generalization. She became wheel chair dependant at age 12, developed feeding difficulties requiring a gastrostomy and lost speech aged 14. She was admitted with status epilepticus and epilepsia partialis continua at age 14 and repeatedly thereafter. EEG showed left temporo-occipital activity. MRI of the brain showed progressive cerebellar atrophy with multiple bilateral cortical stroke-lesions in the occipital lobes. She started deoxyubiquinon 1000 mg per day aged 18 years without any significant improvement.

**Pathology**

Open muscle biopsy from vastus lateralis muscle was performed in patients 1, 2 and 4. Sequential histochemical assay of cytochrome oxidase (COX) and succinate dehydrogenase (SDH) activity was performed as previously described (7). Post-mortem examination of the brain was performed in patient-3 with standard histological methods including hematoxylin and eosin and immunohistochemistry for the astrocytic marker GFAP and microglial marker HLA-DR.

**Genetics**

DNA was purified from blood using the Qiasymphony instrument (Qiagen, Hilden Germany) and muscle using a QIAamp DNA Mini Kit, Qiagen. MtDNA quantification and deletion assessment were performed in muscle DNA from patient 2 as previously described (8). Sanger sequencing of all coding exons of *POLG* and *C10*or*f2* in patient 2 were normal. Whole exome sequencing was performed at HudsonAlpha Institute for Biotechnology (Huntsville, AL) using Roche-NimbleGen Sequence Capture EZ Exome v3 kit and paired-end 100nt sequencing on the Illumina HiSeq. Data quality control and analysis was performed at our in-house pipeline as previously described (9).

**CoQ measurement**

CoQ10 was extracted from muscle homogenate as previously described (10) and its concentration was determined by reverse phase high-performance liquid chromatographywith electrochemical detection.

**RESULTS**:

**Histopathological studies:**

Muscle biopsies from patients 1 (32 years) and 4 (4 years) were unremarkable. The biopsy of patient 2 aged 23 years was similarly normal except for the presence of a single COX negative fibre.

Post-mortem examination of the brain in patient 3 showed severe cerebellar atrophy and multifocal fibrotic infarct-like changes in the occipital and frontal cortex. Microscopic examination showed widespread, multifocal infarct-like changes throughout the cerebral cortex with neuronal loss and eosinophilic neuronal necrosis accompanied by astrocytic and microglial proliferation. Similar changes were also seen in the striatum and amygdala. In the cortex, neuronal loss affected predominantly the superficial (II-III) and deep (IV-V) cortical layers suggestive of laminar cortical necrosis. In the cerebellum and brainstem there was severe neuronal loss, eosinophilic neuronal necrosis and astrogliosis in the cerebellar cortex, affecting the Purkinje cells and neurons of the granule cell layer, dentate nucleus and inferior olivary nucleus of the medulla oblongata, whereas the pons and mesencephalic structures, including the substantia nigra, were preserved.

**CoQ10 levels:**

CoQ10 levels in frozen muscle samples from patients 1 and 2 (table 2) were low, both when related to protein content and the mitochondrial marker, citrate synthase (CS). In patient 1 the CoQ10 concentration was 10% (normalized to protein) and 24% (normalized to CS) of control mean, while in patient 2 the concentration was 34% (normalized to protein) and 60% (normalized to CS).

**Genetic findings:**

In families 1 and 2, *ADCK3* mutations were identified by whole exome sequencing and confirmed by Sanger sequencing. In family 1, we found a homozygous mutation in exon 7: c.895C>T, which is predicted to give the amino acid change p.R299W. In patient 2, we found compound heterozygous mutations in exon 7: c.895C>T, p.R299W and exon 15:c.T1732G, p.F578V. We confirmed these were *in trans* by parental testing.

The findings in family 3 have been reported previously: this patient was homozygous for c.895C>T, p.R299W. Currently, no connection between families 1 and 3 is known. The p.R299W mutation has been reported (6). The novel mutation p.F578V was absent in 400 in house controls and public databases including the 1000 genomes (11) and Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [June 2015 accessed]. Both the 299 and 578 residues are highly conserved and the mutations are predicted to affect the function of the protein by all protein predictions tools in the AlaMut software (Interactive Biosoftware, Rouen, France).

No mtDNA deletions or depletion were found in the muscle of patient 2.

**DISCUSSION**

We report 4 cases of CoQ10 deficiency due to mutations in the *ADCK3* gene. The phenotype of our patients is compatible with earlier reports with all having a slowly progressive cerebellar ataxia with cerebellar atrophy. Additionally, our patients had epilepsy complicated by episodes of status epilepticus and clinical and imaging evidence of stroke-like episodes (4). While ataxia and encephalopathy are well-recognised features of CoQ10 deficiency, the epileptic semiology and stroke like episodes have not been systematically studied.

Including our cases, a total of 78 patients from 45 families with primary CoQ10 deficiency have been reported (6, 12, 13). Epilepsy was present in 16 (20%) the majority of whom (11) had mutations in the *ADCK3* gene suggesting that among patients with CoQ10 deficiency, those with *ADCK3* mutations are particularly prone to epileptogenesis. Of the 11 patients with *ADCK3* mutations and epilepsy, six had epilepsia partialis continua and 5 developed stroke-like episodes with cortical lesions (Table 1&3) (14). EEG in our 4 patients showed that epileptic activity was focused in the occipital and temporal lobes. The combination of occipital predilection and an acute on chronic course with stroke-like lesions on MRI associated with periods of intense epileptic activity are similar to those seen in patients with POLG related disorders (5, 15, 16).

While CoQ10 deficiency is a potentially treatable cause of disease, the steroid resistant nephrotic syndrome is reported to have a better treatment response than the neurological features. Seizures appear to respond poorly to oral CoQ10 supplementation (6, 12, 13, 17-25) and this may be due to reduced oral bioavailability. CoQ10 is poorly absorbed and as a lipid- soluble factor must be ingested together with significant quantities of fat to facilitate uptake. Bioavailability will depend both on dosage and how much crosses the blood-brain barrier (14). In the absence of formal trials these data are currently unavailable. Three of our patients have received oral deoxyubiquinone: one has not been on treatment long (patient 1) while another (patient 4) started late and was already immobilised meaning that motor benefits would be hard to detect. Patient 2 showed a measurable improvement of ataxia. While improvement of the ataxia has been described previously (14), no definite antiepileptic effect has been shown. A potential preventative effect with regard to status epilepticus and associated stroke-like episodes cannot be excluded, but showing this will require systematic longitudinal studies, which are currently lacking. Moreover, as in our patient4, lack of clinical response in some patients may be due to delayed treatment start (18, 26). Thus, further studies are needed to characterise therapeutic responses to different CoQ10 derivatives, doses and organ-specific bioavailability.

In conclusion, we report that patients with *ADCK3* mutations can mimic the phenotype seen in POLG-related encephalopathy with progressive cerebellar ataxia complicated by epilepsy with occipital predilection, status epilepticus and associated stroke-like episodes. We recommend, therefore, mutations in *ADCK3* gene be considered in the differential diagnosis of patients with POLG-like phenotypes.

**Acknowledgements:**

We thank patients and family for contributing for this study. We also thank Roberto Bellavia for his technical support in CoQ10 measurement.

**References:**

1. Quinzii CM, Lopez LC, Naini A, DiMauro S, Hirano M. Human CoQ10 deficiencies. BioFactors (Oxford, England). 2008;32(1-4):113-8.

2. Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochimica et biophysica acta. 2004;1660(1-2):171-99.

3. Horvath R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ 10). Journal of inherited metabolic disease. 2012;35(4):679-87.

4. Doimo M, Desbats MA, Cerqua C, Cassina M, Trevisson E, Salviati L. Genetics of coenzyme q10 deficiency. Molecular syndromology. 2014;5(3-4):156-62.

5. Engelsen BA, Tzoulis C, Karlsen B, Lillebo A, Laegreid LM, Aasly J, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain : a journal of neurology. 2008;131(Pt 3):818-28.

6. Horvath R, Czermin B, Gulati S, Demuth S, Houge G, Pyle A, et al. Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3. Journal of neurology, neurosurgery, and psychiatry. 2012;83(2):174-8.

7. Old SL, Johnson MA. Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. The Histochemical journal. 1989;21(9-10):545-55.

8. Tzoulis C, Tran GT, Schwarzlmuller T, Specht K, Haugarvoll K, Balafkan N, et al. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain : a journal of neurology. 2013;136(Pt 8):2393-404.

9. Haugarvoll K, Johansson S, Tzoulis C, Haukanes BI, Bredrup C, Neckelmann G, et al. MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing. Orphanet journal of rare diseases. 2013;8:1.

10. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001;56(7):849-55.

11. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65.

12. Liu YT, Hersheson J, Plagnol V, Fawcett K, Duberley KE, Preza E, et al. Autosomal-recessive cerebellar ataxia caused by a novel ADCK3 mutation that elongates the protein: clinical, genetic and biochemical characterisation. Journal of neurology, neurosurgery, and psychiatry. 2014;85(5):493-8.

13. Blumkin L, Leshinsky-Silver E, Zerem A, Yosovich K, Lerman-Sagie T, Lev D. Heterozygous Mutations in the ADCK3 Gene in Siblings with Cerebellar Atrophy and Extreme Phenotypic Variability. JIMD reports. 2014;12:103-7.

14. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, Lombes A, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. American journal of human genetics. 2008;82(3):623-30.

15. Tzoulis C, Neckelmann G, Mork SJ, Engelsen BE, Viscomi C, Moen G, et al. Localized cerebral energy failure in DNA polymerase gamma-associated encephalopathy syndromes. Brain : a journal of neurology. 2010;133(Pt 5):1428-37.

16. Tzoulis C, Tran GT, Coxhead J, Bertelsen B, Lilleng PK, Balafkan N, et al. Molecular pathogenesis of polymerase gamma-related neurodegeneration. Annals of neurology. 2014;76(1):66-81.

17. Mollet J, Giurgea I, Schlemmer D, Dallner G, Chretien D, Delahodde A, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. The Journal of clinical investigation. 2007;117(3):765-72.

18. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005;65(4):606-8.

19. Jakobs BS, van den Heuvel LP, Smeets RJ, de Vries MC, Hien S, Schaible T, et al. A novel mutation in COQ2 leading to fatal infantile multisystem disease. Journal of the neurological sciences. 2013;326(1-2):24-8.

20. Salviati L, Trevisson E, Rodriguez Hernandez MA, Casarin A, Pertegato V, Doimo M, et al. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. Journal of medical genetics. 2012;49(3):187-91.

21. Heeringa SF, Chernin G, Chaki M, Zhou W, Sloan AJ, Ji Z, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. The Journal of clinical investigation. 2011;121(5):2013-24.

22. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. The Journal of clinical investigation. 2013;123(12):5179-89.

23. Rahman S, Clarke CF, Hirano M. 176th ENMC International Workshop: diagnosis and treatment of coenzyme Q(1)(0) deficiency. Neuromuscular disorders : NMD. 2012;22(1):76-86.

24. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, Lopez LC, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. American journal of human genetics. 2009;84(5):558-66.

25. Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. Journal of inherited metabolic disease. 2015;38(1):145-56.

26. Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, Naini A, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. American journal of human genetics. 2006;79(6):1125-9.

**Table 1 Summary of cases reported in this paper**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Family** | **Patient** | **Onset** | **Age** | | **Cerebellar atrophy** | **Stroke like lesions** | **Epilepsy** | | **Mutations** |
|  |  |  | **Current** | **Death** |  |  | **Type** | **Focus** |  |
| 1 | 1 | 7 | 35 |  | + | - | F,GTC | Occ/Temp | c.895C>T, p.R299W homozygous |
| 2 | 2 | 7 | 34 |  | + | + | F,GTC,EPC | Occ/Temp | c.895C>T,p.R229W, c.1732T>G, p.F578V heterozygote |
| 2 | 3 | 3 |  | 22 | + | + | F,GTC,EPC | Occ/Temp | c.895C>T,p.R229W, c.1732T>G, p.F578V heterozygote |
| 3 | 4 | 2 | 22 |  | + | + | F,GTC,EPC | Occ/Temp | c.895C>T, p.R299W homozygous |

Abbreviations: F – focal seizure; GTC - generalised tonic clonic seizure; EPC- epilepsia partialis continua;

Occ – occipital; Temp – temporal.

**Table 2. CoQ10 levels in patients 1 and 2**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **µg CoQ/g protein** | **µg CoQ/CS** | **Citrate synthase (CS)** |
| **Patient 1** |  | 12.5 | 0.55 | 22.5 |
| **Patient 2** |  | 40.9 | 1.36 | 30 |
| **Control** | Mean | 122 | 2.25 | 53 |
|  | Range | 87-158 | 1.51-2.99 | 34-72 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Families** | **Onset** | **Age** | **Cerebellar** | **Cerebellar** | **Epilepsy** | **Epilepsy** | **Mutations** |
| **(N=Patients)** | **(years)** | **(years)** | **ataxia** | **atrophy** |  | **classification** |  |
| 1 (4) | 7-11 | 29-42 | + | + | NK | NK | c.1398+2T>C homozygous |
| 2(1) | 4 | 18 | + | + | NK | NK | c.500\_521 delinsTTG homozygous |
| 3(1) | 5 | 17 | + | + | NK | NK | p.Y514C/ p.T584del |
| 4(1) | 3 | 30 | + | + | NK | NK | p.L314\_Q 360del/ p.G549S |
| 5(1) | 1,5 | 16 | + | + SLL | + | GTC/ EPC | p.E551K homozygous |
| 6(2) | 1,5 | 13,14 | + | + SLL | + | GTC/ EPC | p.R213W/ p.G272V |
| 7(1) | 3 | 17 | + | + | + | Myoclonus | p.G272D/ c.1812\_13insG |
| 8(3) | 3-9 | 26-31 | + | + | + | Myoclonus | p.R348X homozygous |
| 9(2) | 1,2 | 20,30 | + | + | NK | NK | p.R348X/ p.L379X |
| 10(2) | 15,18 | 46/NK | + | + | + | Myoclonus | c.811C>T, p.R271C/ c.911G>A, pA304V |
| 11(1) | 27 | 50 | + | + | + | Myoclonus | c.911C>T, p.A304V homozygous |
| 12(1) | 1 | 18 | + | + | + | NK | c.895C>T, p.R299W homozygous |
| 13(2) | 1,5 -2 | 20,26 | + | + | - |  | c.1286A>G, p.Y429C heterozygous |
| 14(2) | 2-NK | 20,32 | + | + | NK |  | p.T584delACC(c.1750\_1752delACC) |
|  |  |  |  |  |  |  | and p.P502R |
| 15(2) | 10,14 | 35,32 | + | + | NK |  | C.1844\_1845insG, p.S616Lfs\*114 |

**Table 3. Summary of previously reported patients with ADCK3 mutations.**

Abbreviation: NK-Not known; + Present; - Absent; EPC- epilepsia partialis continua; GTC- generalised tonic clonic seizure,

SLL-Stroke like lesions.

**Figure legends**

Figure 1

MRI (A-C) and FDG-PET (D-F) of the brain of patient 2 at the age of 34 years. A: sagittal T1-weighted image showing midline cerebellar atrophy, particularly of the superior vermis. B: axial T2-weighted image showing symmetrical hyperintense signal in the nucleus dentatus consistent with “white teeth” sign which often accompanies efferent cerebellar degeneration (i.e. loss of cerebellar output). C: axial T2-weighted image showing a stroke-like lesion in the right lateral occipital lobe. D-F: FDG-PET scan of the brain showing decreased glucose metabolism in the cerebellum (D and E) and right occipital lesion (F).

Figure 1

